- 1.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol
2018;69:182–236. [
PubMed: 29628281]
- 2.
Villanueva
A. Hepatocellular carcinoma. N Engl J Med
2019;380:1450–62. 10.1056/NEJMra1713263 [
PubMed: 30970190] [
CrossRef]
- 3.
- 4.
Oken
MM, Creech
RH, Tormey
DC, Horton
J, Davis
TE, McFadden
ET, Carbone
PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol
1982;5:649–56. 10.1097/00000421-198212000-00014 [
PubMed: 7165009] [
CrossRef]
- 5.
- 6.
- 7.
Park
JW, Chen
M, Colombo
M, Roberts
LR, Schwartz
M, Chen
PJ, et al.
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int
2015;35:2155–66. 10.1111/liv.12818 [
PMC free article: PMC4691343] [
PubMed: 25752327] [
CrossRef]
- 8.
- 9.
Mazzaferro
V, Regalia
E, Doci
R, Andreola
S, Pulvirenti
A, Bozzetti
F, et al.
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med
1996;334:693–9. 10.1056/NEJM199603143341104 [
PubMed: 8594428] [
CrossRef]
- 10.
- 11.
National Institute for Health and Care Excellence (NICE). Sorafenib for Treating Advanced Hepatocellular Carcinoma [TA474]. London: NICE; 2017. URL:
www.nice.org.uk/guidance/ta474 (accessed 29 May 2019).
- 12.
National Institute for Health and Care Excellence (NICE). Lenvatinib for Untreated Advanced Hepatocellular Carcinoma [TA551]. London: NICE; 2018. URL:
www.nice.org.uk/guidance/ta551 (accessed 29 May 2019).
- 13.
National Institute for Health and Care Excellence (NICE). Regorafenib for Previously Treated Advanced Hepatocellular Carcinoma [TA555]. London: NICE; 2019. URL:
www.nice.org.uk/guidance/ta555 (accessed 29 May 2019).
- 14.
National Institute for Health and Care Excellence (NICE). Selective Internal Radiation Therapy for Primary Hepatocellular Carcinoma. Interventional Procedures Guidance [IPG460]. London: NICE; 2013. URL:
www.nice.org.uk/guidance/ipg460 (accessed 8 May 2019).
- 15.
Centre for Reviews and Dissemination. CRD’s Guidance for Undertaking Reviews in Health Care. York: CRD, University of York; 2009.
- 16.
- 17.
- 18.
- 19.
Vilgrain
V, Pereira
H, Assenat
E, Guiu
B, Ilonca
AD, Pageaux
GP, et al.
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled Phase 3 trial. Lancet Oncol
2017;18:1624–36. 10.1016/S1470-2045(17)30683-6 [
PubMed: 29107679] [
CrossRef]
- 20.
Bouattour
M, Assenat
E, Guiu
B, Ilonca Alina
D, Pageaux
GP, Sibert
A, et al.
LBA-001 Efficacy, tolerability and impact on quality of life of selective internal radiation therapy (with yttrium-90 resin microspheres) or sorafenib in patients with locally advanced hepatocellular carcinoma: the SARAH trial. Ann Oncol
2017;28(Suppl. 3):iii150–3.
- 21.
Chow
PKH, Gandhi
M, Tan
SB, Khin
MW, Khasbazar
A, Ong
J, et al.
SIRveNIB: Selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol
2018;36:1913–21. 10.1200/JCO.2017.76.0892 [
PubMed: 29498924] [
CrossRef]
- 22.
Kolligs
FT, Bilbao
JI, Jakobs
T, Iñarrairaegui
M, Nagel
JM, Rodriguez
M, et al.
Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int
2015;35:1715–21. 10.1111/liv.12750 [
PubMed: 25443863] [
CrossRef]
- 23.
Pitton
MB, Kloeckner
R, Ruckes
C, Wirth
GM, Eichhorn
W, Wörns
MA, et al.
Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol
2015;38:352–60. 10.1007/s00270-014-1012-0 [
PMC free article: PMC4355443] [
PubMed: 25373796] [
CrossRef]
- 24.
Ricke
J, Bulla
K, Kolligs
F, Peck-Radosavljevic
M, Reimer
P, Sangro
B, et al.
Safety and toxicity of radioembolization plus sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC. Liver Int
2015;35:620–6. 10.1111/liv.12622 [
PubMed: 24930619] [
CrossRef]
- 25.
Salem
R, Gordon
AC, Mouli
S, Hickey
R, Kallini
J, Gabr
A, et al.
Y90 Radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology
2016;151:1155–63.e2. 10.1053/j.gastro.2016.08.029 [
PMC free article: PMC5124387] [
PubMed: 27575820] [
CrossRef]
- 26.
Gabr
A, Kallini
JR, Lewandowski
RJ, Salem
R. Fluoroscopic radiation exposure in chemoembolization and radioembolization: results from a prospective randomized study. J Vasc Interv Radiol
2017;28:1272–3. 10.1016/j.jvir.2017.05.005 [
PubMed: 28841927] [
CrossRef]
- 27.
Gordon
A, Lewandowski
R, Hickey
R, Kallini
J, Gabr
A, Sato
K, et al.
Prospective randomized phase 2 study of chemoembolization versus radioembolization in hepatocellular carcinoma: results from the PREMIERE trial. J Vasc Interv Radiol
2016;27:S61–2. 10.1016/j.jvir.2015.12.168 [
CrossRef]
- 28.
Kulik
L, Vouche
M, Koppe
S, Lewandowski
RJ, Mulcahy
MF, Ganger
D, et al.
Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma. J Hepatol
2014;61:309–17. 10.1016/j.jhep.2014.03.023 [
PubMed: 24681342] [
CrossRef]
- 29.
Lewandowski
RJ, Andreoli
JM, Hickey
R, Kallini
JR, Gabr
A, Baker
T, et al.
Angiogenic response following radioembolization: results from a randomized pilot study of yttrium-90 with or without sorafenib. J Vasc Interv Radiol
2016;27:1329–36. 10.1016/j.jvir.2016.03.043 [
PubMed: 27266362] [
CrossRef]
- 30.
Vouche
M, Kulik
L, Atassi
R, Memon
K, Hickey
R, Ganger
D, et al.
Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: imaging analysis from a prospective randomized trial of Y90 +/− sorafenib. Hepatology
2013;58:1655–66. 10.1002/hep.26487 [
PMC free article: PMC5097874] [
PubMed: 23703789] [
CrossRef]
- 31.
Kirchner
T, Marquardt
S, Werncke
T, Kirstein
MM, Brunkhorst
T, Wacker
F, et al.
Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma. Abdom Radiol
2019;44:1554–61. 10.1007/s00261-018-1802-y [
PubMed: 30311050] [
CrossRef]
- 32.
El Fouly
A, Ertle
J, El Dorry
A, Shaker
MK, Dechêne
A, Abdella
H, et al.
In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?
Liver Int
2015;35:627–35. 10.1111/liv.12637 [
PubMed: 25040497] [
CrossRef]
- 33.
Salem
R, Gilbertsen
M, Butt
Z, Memon
K, Vouche
M, Hickey
R, et al.
Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol
2013;11:1358–65.e1. 10.1016/j.cgh.2013.04.028 [
PubMed: 23644386] [
CrossRef]
- 34.
Memon
K, Kulik
L, Lewandowski
RJ, Gupta
R, Ryu
RK, Miller
FH, et al.
Prospective evaluation of patients with early-/intermediate-stage hepatocellular carcinoma with disease progression following arterial locoregional therapy: candidacy for systemic treatment or clinical trials. J Vasc Interv Radiol
2013;24:1189–97.e2. 10.1016/j.jvir.2012.12.025 [
PubMed: 23474327] [
CrossRef]
- 35.
Hickey
R, Mouli
S, Kulik
L, Desai
K, Thornburg
B, Ganger
D, et al.
Independent analysis of albumin-bilirubin grade in a 765-patient cohort treated with transarterial locoregional therapy for hepatocellular carcinoma. J Vasc Interv Radiol
2016;27:795–802. 10.1016/j.jvir.2016.03.005 [
PubMed: 27038686] [
CrossRef]
- 36.
Maccauro
M, Sposito
C, Chiesa
C, Romito
R, Spreafico
C, Morosi
C, et al.
Trans-arterial radioembolization (TARE) with Y90 glass microspheres plus sorafenib versus tare alone for the treatment of unresectable hepatocellular carcinoma (HCC): a matched case-control study. Eur J Nucl Med Mol Imaging
2014;41(Suppl. 2):S291.
- 37.
Woodall
CE, Scoggins
CR, Ellis
SF, Tatum
CM, Hahl
MJ, Ravindra
KV, et al.
Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis?
J Am Coll Surg
2009;208:375–82. 10.1016/j.jamcollsurg.2008.12.009 [
PubMed: 19317999] [
CrossRef]
- 38.
Biederman
DM, Tabori
NE, Titano
JJ, Pierobon
ES, Fischman
AM, Patel
RS, et al.
Outcomes of yttrium-90 therapy in the treatment of hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT): resin-based vs. glassbased microspheres. J Vasc Interv Radiol
2015;26:S109–10. 10.1016/j.jvir.2014.12.296 [
CrossRef]
- 39.
Biederman
DM, Titano
JJ, Tabori
NE, Pierobon
ES, Alshebeeb
K, Schwartz
M, et al.
Outcomes of radioembolization in the treatment of hepatocellular carcinoma with portal vein invasion: resin versus glass microspheres. J Vasc Interv Radiol
2016;27:812–21.e2. 10.1016/j.jvir.2016.01.147 [
PubMed: 27062356] [
CrossRef]
- 40.
Van Der Gucht
A, Jreige
M, Denys
A, Blanc-Durand
P, Boubaker
A, Pomoni
A, et al.
Resin versus glass microspheres for 90Y transarterial radioembolization: comparing survival in unresectable hepatocellular carcinoma using pretreatment partition model dosimetry. J Nucl Med
2017;58:1334–40. 10.2967/jnumed.116.184713 [
PubMed: 28082436] [
CrossRef]
- 41.
Bhangoo
MS, Karnani
DR, Hein
PN, Giap
H, Knowles
H, Issa
C, et al.
Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma. J Gastrointest Oncol
2015;6:469–78. 10.3978/j.issn.2078-6891.2015.056 [
PMC free article: PMC4570909] [
PubMed: 26487939] [
CrossRef]
- 42.
d’Abadie
P, Hesse
M, Jamar
F, Lhommel
R, Walrand
S. 90Y TOF-PET based EUD reunifies patient survival prediction in resin and glass microspheres radioembolization of HCC tumours. Phys Med Biol
2018;63:245010. 10.1088/1361-6560/aaf205 [
PubMed: 30524029] [
CrossRef]
- 43.
Cho
YY, Lee
M, Kim
HC, Chung
JW, Kim
YH, Gwak
GY, et al.
Radioembolization is a safe and effective treatment for hepatocellular carcinoma with portal vein thrombosis: a propensity score analysis. PLOS ONE
2016;11:e0154986. 10.1371/journal.pone.0154986 [
PMC free article: PMC4858257] [
PubMed: 27149067] [
CrossRef]
- 44.
de la Torre
MA, Buades-Mateu
J, de la Rosa
PA, Lué
A, Bustamante
FJ, Serrano
MT, et al.
A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib. Liver Int
2016;36:1206–12. 10.1111/liv.13098 [
PubMed: 26910784] [
CrossRef]
- 45.
Gramenzi
A, Golfieri
R, Mosconi
C, Cappelli
A, Granito
A, Cucchetti
A, et al.
Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int
2015;35:1036–47. 10.1111/liv.12574 [
PubMed: 24750853] [
CrossRef]
- 46.
Soydal
C, Arslan
MF, Kucuk
ON, Idilman
R, Bilgic
S. Comparison of survival, safety, and efficacy after transarterial chemoembolization and radioembolization of Barcelona Clinic Liver Cancer stage B-C hepatocellular cancer patients. Nucl Med Commun
2016;37:646–9. 10.1097/MNM.0000000000000486 [
PubMed: 26905317] [
CrossRef]
- 47.
Salem
R, Lewandowski
RJ, Kulik
L, Wang
E, Riaz
A, Ryu
RK, et al.
Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology
2011;140:497–507.e2. 10.1053/j.gastro.2010.10.049 [
PMC free article: PMC3129335] [
PubMed: 21044630] [
CrossRef]
- 48.
Moreno-Luna
LE, Yang
JD, Sanchez
W, Paz-Fumagalli
R, Harnois
DM, Mettler
TA, et al.
Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol
2013;36:714–23. 10.1007/s00270-012-0481-2 [
PMC free article: PMC3594060] [
PubMed: 23093355] [
CrossRef]
- 49.
Akinwande
O, Philips
P, Scoggins
C, Martin
RC. Radioembolization versus chemoembolization (DEBDOX) for the treatment of unresectable hepatocellular carcinoma: a propensity matched study. Anticancer Res
2016;36:239–46. [
PubMed: 26722049]
- 50.
Akinwande
O, Martin
R. Is radioembolization equivalent to chemoembolization (DEBDOX) for the treatment of HCC? A propensity matched observational study. J Vasc Interv Radiol
2016;27:S248. 10.1016/j.jvir.2015.12.633 [
CrossRef]
- 51.
Radosa
CG, Radosa
JC, Grosche-Schlee
S, Zöphel
K, Plodeck
V, Kühn
JP, et al.
Holmium-166 radioembolization in hepatocellular carcinoma: feasibility and safety of a new treatment option in clinical practice. Cardiovasc Intervent Radiol
2019;42:405–12. 10.1007/s00270-018-2133-7 [
PubMed: 30603976] [
CrossRef]
- 52.
Steel
J, Baum
A, Carr
B. Quality of life in patients diagnosed with primary hepatocellular carcinoma: hepatic arterial infusion of Cisplatin versus 90-Yttrium microspheres (Therasphere). Psycho-Oncology
2004;13:73–9. 10.1002/pon.725 [
PubMed: 14872525] [
CrossRef]
- 53.
Moroz
P, Anderson
JE, Van Hazel
G, Gray
BN. Effect of selective internal radiation therapy and hepatic arterial chemotherapy on normal liver volume and spleen volume. J Surg Oncol
2001;78:248–52. 10.1002/jso.1162 [
PubMed: 11745819] [
CrossRef]
- 54.
Maccauro
M, Spreafico
C, Chiesa
C, Mira
M, De Nila
M, Romito
R, et al.
Personalized treatment planning in radioembolization of hepatocarcinoma with 90 Y glass microspheres: update of clinical outcomes in the Milan experience. Eur J Nucl Med Mol Imaging
2016;43(Suppl. 1):S10.
- 55.
Pellerito
RE, Codegone
A, Tabone
M, Richetta
E, Miranti
A, Stasi
M. Intrahepatic treatment of advanced hepatocellular carcinoma with 90Y Sirtex or 131I Lipiodol: preliminary results of a case control study. Clin Transl Imaging
2013;1(Suppl. 1):S126–7.
- 56.
Lammer
J, Malagari
K, Vogl
T, Pilleul
F, Denys
A, Watkinson
A, et al.
Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol
2010;33:41–52. 10.1007/s00270-009-9711-7 [
PMC free article: PMC2816794] [
PubMed: 19908093] [
CrossRef]
- 57.
Vogl
TJ, Lammer
J, Lencioni
R, Malagari
K, Watkinson
A, Pilleul
F, et al.
Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol
2011;197:W562–70. 10.2214/AJR.10.4379 [
PubMed: 21940527] [
CrossRef]
- 58.
Golfieri
R, Giampalma
E, Renzulli
M, Cioni
R, Bargellini
I, Bartolozzi
C, et al.
Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer
2014;111:255–64. 10.1038/bjc.2014.199 [
PMC free article: PMC4102934] [
PubMed: 24937669] [
CrossRef]
- 59.
Sacco
R, Bargellini
I, Bertini
M, Bozzi
E, Romano
A, Petruzzi
P, et al.
Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol
2011;22:1545–52. 10.1016/j.jvir.2011.07.002 [
PubMed: 21849247] [
CrossRef]
- 60.
van Malenstein
H, Maleux
G, Vandecaveye
V, Heye
S, Laleman
W, van Pelt
J, et al.
A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie
2011;34:368–76. 10.1159/000329602 [
PubMed: 21734423] [
CrossRef]
- 61.
Llovet
JM, Real
MI, Montaña
X, Planas
R, Coll
S, Aponte
J, et al.
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet
2002;359:1734–9. 10.1016/S0140-6736(02)08649-X [
PubMed: 12049862] [
CrossRef]
- 62.
Kawai
S, Okamura
J, Ogawa
M, Ohashi
Y, Tani
M, Inoue
J, et al.
Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma – a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). Cancer Chemother Pharmacol
1992;31(Suppl. 1):S1–6. 10.1007/BF00687096 [
PubMed: 1281041] [
CrossRef]
- 63.
Chang
JM, Tzeng
WS, Pan
HB, Yang
CF, Lai
KH. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer
1994;74:2449–53. 10.1002/1097-0142(19941101)74:9<2449::aid-cncr2820740910>3.0.co;2-4 [
PubMed: 7922999] [
CrossRef]
- 64.
Meyer
T, Kirkwood
A, Roughton
M, Beare
S, Tsochatzis
E, Yu
D, et al.
A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer
2013;108:1252–9. 10.1038/bjc.2013.85 [
PMC free article: PMC3619271] [
PubMed: 23449352] [
CrossRef]
- 65.
Yu
SC, Hui
JW, Hui
EP, Chan
SL, Lee
KF, Mo
F, et al.
Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization. Radiology
2014;270:607–20. 10.1148/radiol.13130498 [
PubMed: 24126369] [
CrossRef]
- 66.
Malagari
K, Pomoni
M, Kelekis
A, Pomoni
A, Dourakis
S, Spyridopoulos
T, et al.
Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol
2010;33:541–51. 10.1007/s00270-009-9750-0 [
PubMed: 19937027] [
CrossRef]
- 67.
Brown
KT, Do
RK, Gonen
M, Covey
AM, Getrajdman
GI, Sofocleous
CT, et al.
Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol
2016;34:2046–53. 10.1200/JCO.2015.64.0821 [
PMC free article: PMC4966514] [
PubMed: 26834067] [
CrossRef]
- 68.
Eisenhauer
EA, Therasse
P, Bogaerts
J, Schwartz
LH, Sargent
D, Ford
R, et al.
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). EJC
2009;45:228–47. 10.1016/j.ejca.2008.10.026 [
PubMed: 19097774] [
CrossRef]
- 69.
Sangro
B, Carpanese
L, Cianni
R, Golfieri
R, Gasparini
D, Ezziddin
S, et al.
Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology
2011;54:868–78. 10.1002/hep.24451 [
PubMed: 21618574] [
CrossRef]
- 70.
Cardiovascular and Interventional Radiological Society of Europe. CIRSE Registry for SIR-spheres Therapy (CIRT). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US); 2014. URL:
https://ClinicalTrials.gov/show/NCT02305459 (accessed 1 February 2019).
- 71.
Vanderbilt-Ingram Cancer Center. Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: The RESIN Study. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US); 2016. URL:
https://ClinicalTrials.gov/show/NCT02685631 (accessed 1 February 2019).
- 72.
Taipei Veterans General Hospital. REgistry of Selective Internal Radiation Therapy in TaiwaN (RESIN). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US); 2017. URL:
https://ClinicalTrials.gov/show/NCT03292991 (accessed 1 February 2019).
- 73.
Gebski
V, Gibbs
E, Gandhi
M, Chatellier
G, Dinut
A, Pereira
H, et al.
VESPRO: an individual patient data prospective meta-analysis of selective internal radiation therapy versus sorafenib for advanced, locally advanced, or recurrent hepatocellular carcinoma of the SARAH and SIRveNIB trials. JMIR Res Protoc
2017;6:e17. 10.2196/resprot.7016 [
PMC free article: PMC5332836] [
PubMed: 28202430] [
CrossRef]
- 74.
BTG Ltd. Efficacy Evaluation of Therasphere in Patients with Inoperable Liver Cancer (STOP-HCC). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US); 2012. URL:
https://clinicaltrials.gov/show/nct01556490 (accessed 28 January 2019).
- 75.
UMC Utrecht. HEPAR Primary: Holmium-166-Radioembolization in Hepatocellular Carcinoma Patients. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US); 2017. URL:
https://ClinicalTrials.gov/show/NCT03379844 (accessed 1 February 2019).
- 76.
Leiden University Medical Center. Holmium Radioembolization as Adjuvant Treatment to RFA for Early Stage HCC: Dose Finding Study (HORA EST HCC). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US); 2018. URL:
https://ClinicalTrials.gov/show/NCT03437382 (accessed 1 February 2019).
- 77.
- 78.
Reinders
MT, Hoffmann
RT, Lam
MG, Radosa
C. First Results of Homium-166 Radioembolisation Compared with Yttrium-90 Radioembolisation in HCC Patients. Leuven: Terumo Europe NV; 2019.
- 79.
Kallini
JR, Gabr
A, Thorlund
K, Balijepalli
C, Ayres
D, Kanters
S, et al.
Comparison of the adverse event profile of TheraSphere® with SIR-Spheres® for the treatment of unresectable hepatocellular carcinoma: a systematic review. Cardiovasc Intervent Radiol
2017;40:1033–43. 10.1007/s00270-017-1594-4 [
PubMed: 28246879] [
CrossRef]
- 80.
Llovet
JM, Ricci
S, Mazzaferro
V, Hilgard
P, Gane
E, Blanc
JF, et al.
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med
2008;359:378–90. 10.1056/NEJMoa0708857 [
PubMed: 18650514] [
CrossRef]
- 81.
Kudo
M, Finn
RS, Qin
S, Han
KH, Ikeda
K, Piscaglia
F, et al.
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet
2018;391:1163–73. 10.1016/S0140-6736(18)30207-1 [
PubMed: 29433850] [
CrossRef]
- 82.
Lu
G, Ades
AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med
2004;23:3105–24. 10.1002/sim.1875 [
PubMed: 15449338] [
CrossRef]
- 83.
Memon
K, Kulik
LM, Lewandowski
RJ, Wang
E, Wang
J, Ryu
RK, et al.
Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization. J Vasc Interv Radiol
2014;25:1056–66. 10.1016/j.jvir.2014.01.010 [
PMC free article: PMC5097871] [
PubMed: 24613269] [
CrossRef]
- 84.
Vilgrain
V, Bouattour
M, Sibert
A, Lebtahi
R, Ronot
M, Pageaux
GP, et al.
SARAH: a randomised controlled trial comparing efficacy and safety of selective internal radiation therapy (with yttrium-90 microspheres) and sorafenib in patients with locally advanced hepatocellular carcinoma. J Hepatol
2017;66:S85–6. 10.1016/S0168-8278(17)30436-1 [
CrossRef]
- 85.
Cho
MT, Kessler
J, Park
J, Singh
G, Chen
YJ, Ituarte
PHG, et al.
A single institute retrospective trial of concurrent chemotherapy with SIR-Sphere versus SIR-Sphere alone in patients with chemotherapy-resistant colorectal cancer liver metastases. J Clin Oncol
2016;34. 10.1200/jco.2016.34.4_suppl.770 [
PMC free article: PMC5582041] [
PubMed: 28890809] [
CrossRef]
- 86.
Dias
S, Welton
NJ, Sutton
AJ, Ades
AE. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-analysis of Randomised Controlled Trials. Sheffield: Decision Support Unit, ScHARR, University of Sheffield; 2014. [
PubMed: 27466657]
- 87.
Guyot
P, Ades
AE, Ouwens
MJ, Welton
NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol
2012;12:9. 10.1186/1471-2288-12-9 [
PMC free article: PMC3313891] [
PubMed: 22297116] [
CrossRef]
- 88.
Philips
Z, Bojke
L, Sculpher
M, Claxton
K, Golder
S. Good practice guidelines for decision-analytic modelling in health technology assessment. PharmacoEconomics
2006;24:355–71. 10.2165/00019053-200624040-00006 [
PubMed: 16605282] [
CrossRef]
- 89.
Rognoni
C, Ciani
O, Sommariva
S, Tarricone
R. Real-world data for the evaluation of transarterial radioembolization versus sorafenib in hepatocellular carcinoma: a cost-effectiveness analysis. Value Health
2017;20:336–44. 10.1016/j.jval.2016.09.2397 [
PubMed: 28292478] [
CrossRef]
- 90.
Rognoni
C, Ciani
O, Sommariva
S, Tarricone
R. Treatment sequence in intermediate stage hepatocellular carcinoma: a cost-effectiveness analysis of two approaches with trans-arterial radioembolization. Value Health
2017;20:A247. 10.1016/j.jval.2016.09.2397 [
PubMed: 28292478] [
CrossRef]
- 91.
Rostambeigi
N, Dekarske
A, Austin
E, Golzarian
J, Cressman
E. Simulation study on cost-effectiveness of radioembolization compared with trans-arterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol
2014;25:S104–5. 10.1016/j.jvir.2013.12.292 [
PubMed: 24861664] [
CrossRef]
- 92.
Rostambeigi
N, Dekarske
AS, Austin
EE, Golzarian
J, Cressman
EN. Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Vasc Interv Radiol
2014;25:1075–84. 10.1016/j.jvir.2014.04.014 [
PubMed: 24861664] [
CrossRef]
- 93.
Marqueen
KE, Ang
C, Mazumdar
M, Buckstein
M, Ferket
BS. Cost-effectiveness analysis of selective internal radiation therapy with yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys
2018;102:e402. 10.1016/j.ijrobp.2018.07.1185 [
CrossRef]
- 94.
Chaplin
S, Taylor
M, Lapon
J, White
J. Economic evaluation of glass yttrium-90 microspheres versus sorafenib for the treatment of advanced hepatocellular carcinoma: cost effectiveness analysis in the United Kingdom. Cardiovasc Intervent Radiol
2015;38:S279–80.
- 95.
Parikh
ND, Singal
AG, Kulik
LM, Hutton
D. Cost-effectiveness of sorafenib versus selective internal radiation therapy for patients with advanced hepatocellular carcinoma. Hepatology
2018;68(Suppl. 1):532A–3A.
- 96.
Palmer
D, Ross
P, Shah
T, Yu
D, Shergill
S, Patterson
K, et al.
Cost effectiveness of selective internal radiation therapy (SIRT) with Y- 90 resin microspheres versus sorafenib in Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma patients in the UK. Ann Oncol
2017;28(Suppl. 5):239–40. 10.1093/annonc/mdx369.087 [
CrossRef]
- 97.
Rognoni
C, Ciani
O, Sommariva
S, Tarricone
R. Cost-effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma. J Comp Eff Res
2018;7:209–21. 10.2217/cer-2017-0050 [
PubMed: 29231047] [
CrossRef]
- 98.
Llovet
JM, Finn
RS. Negative phase 3 study of 90Y microspheres versus sorafenib in HCC. Lancet Oncol
2018;19:e69. 10.1016/S1470-2045(18)30025-1 [
PubMed: 29413470] [
CrossRef]
- 99.
- 100.
- 101.
Bruix
J, Qin
S, Merle
P, Granito
A, Huang
YH, Bodoky
G, et al.
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet
2017;389:56–66. 10.1016/S0140-6736(16)32453-9 [
PubMed: 27932229] [
CrossRef]
- 102.
Sirtex Medical Ltd. Sirtex Medical Company Evidence Submission: SIR-Spheres Y-90 Resin Microspheres. Woburn, MA: Sirtex Medical Ltd; 2019.
- 103.
BTG. BTG Company Evidence Submission for TheraSphere. London: BTG; 2019.
- 104.
Terumo. Terumo Company Evidence Submission: Selective Internal Radiation Therapy (SIRT) with Holmium-166 Microspheres (QuiremSpheres) for Treating Unresectable Hepatocellular Carcinoma and Holmium-166 Microspheres Work-up Procedure (QuiremScout). Tokyo: Terumo; 2019.
- 105.
Fateen
W, Khan
F, O’Neill
RJ, James
MW, Ryder
SD, Aithal
GP. Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma. J Hepatocell Carcinoma
2017;4:123–30. 10.2147/JHC.S144068 [
PMC free article: PMC5652915] [
PubMed: 29082223] [
CrossRef]
- 106.
Curtis
L, Burns
A. Unit Costs of Health and Social Care 2018. Canterbury: PSSRU, University of Kent; 2018.
- 107.
- 108.
Salem
R, Gabr
A, Riaz
A, Mora
R, Ali
R, Abecassis
M, et al.
Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. Hepatology
2018;68:1429–40. 10.1002/hep.29691 [
PubMed: 29194711] [
CrossRef]
- 109.
National Institute for Health and Care Excellence (NICE). Guselkumab for Treating Moderate to Severe Plaque Psoriasis. London: NICE; 2018. URL:
www.nice.org.uk/guidance/ta521 (accessed 21 August 2019).
- 110.
National Institute for Health and Care Excellence (NICE). Golimumab for Treating Non-radiographic Axial Spondyloarthritis. London: NICE; 2018. URL:
www.nice.org.uk/guidance/ta497 (accessed 21 August 2019).
- 111.
National Institute for Health and Care Excellence (NICE). Aflibercept for Treating Choroidal Neovascularisation. London: NICE; 2017. URL:
www.nice.org.uk/Guidance/TA486 (accessed 21 August 2019).
- 112.
Kanwal
F, Befeler
A, Chari
RS, Marrero
J, Kahn
J, Afdhal
N, et al.
Potentially curative treatment in patients with hepatocellular cancer – results from the liver cancer research network. Aliment Pharmacol Ther
2012;36:257–65. 10.1111/j.1365-2036.2012.05174.x [
PubMed: 22670798] [
CrossRef]
- 113.
Longworth
L, Yang
Y, Young
T, Mulhern
B, Hernández Alava
M, Mukuria
C, et al.
Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Technol Assess
2014;18(9). 10.3310/hta18090 [
PMC free article: PMC4780954] [
PubMed: 24524660] [
CrossRef]
- 114.
CIRSE Registry for SIR-Spheres Therapy. CIRSE Registry for SIR-Spheres Therapy (CIRT): Preliminary Data on Patients with HCC. Vienna: Cardiovascular and Interventional Radiological Society of Europe; 2019.
- 115.
Joint Formulary Committee. British National Formulary (Online). BMJ Group and Pharmaceutical Press; 2019. URL:
www.medicinescomplete.com (accessed 17 April 2019).
- 116.
- 117.
Latimer
N. NICE DSU Technical Support Document 14: Survival Analysis for Economic Evaluations Alongside Clinical Trials - Extrapolation with Patient-Level Data. Sheffield: Decision Support Unit, School of Health and Related Research, University of Sheffield; 2013. 10.1177/0272989X12472398 [
PubMed: 27905716] [
CrossRef]
- 118.
Lewandowski
RJ, Kulik
LM, Riaz
A, Senthilnathan
S, Mulcahy
MF, Ryu
RK, et al.
A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant
2009;9:1920–8. 10.1111/j.1600-6143.2009.02695.x [
PubMed: 19552767] [
CrossRef]
- 119.
Yao
FY, Xiao
L, Bass
NM, Kerlan
R, Ascher
NL, Roberts
JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant
2007;7:2587–96. 10.1111/j.1600-6143.2007.01965.x [
PubMed: 17868066] [
CrossRef]
- 120.
NHS Blood and Transplant. Annual Report on Liver Transplantation. London: NHS Blood and Transplant; 2018.
- 121.
NHS England. Liver Transplantation Service (Adults): London: NHS England; 2017.
- 122.
Bellavance
EC, Lumpkins
KM, Mentha
G, Marques
HP, Capussotti
L, Pulitano
C, et al.
Surgical management of early-stage hepatocellular carcinoma: resection or transplantation?
J Gastrointest Surg
2008;12:1699–708. 10.1007/s11605-008-0652-2 [
PubMed: 18709418] [
CrossRef]
- 123.
Gordon-Weeks
AN, Snaith
A, Petrinic
T, Friend
PJ, Burls
A, Silva
MA. Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria. Br J Surg
2011;98:1201–8. 10.1002/bjs.7561 [
PubMed: 21618496] [
CrossRef]
- 124.
National Institute for Health and Care Excellence (NICE). Lenvatinib for Untreated Advanced Hepatocellular Carcinoma [TA551] - Evidence. London: NICE; 2018. URL:
www.nice.org.uk/guidance/ta551/evidence (accessed 28 August 2019).
- 125.
Lim
KC, Wang
VW, Siddiqui
FJ, Shi
L, Chan
ES, Oh
HC, et al.
Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria. Hepatology
2015;61:227–37. 10.1002/hep.27135 [
PubMed: 24638991] [
CrossRef]
- 126.
Ratcliffe
J, Buxton
M, Young
T, Longworth
L. Determining priority for liver transplantation: a comparison of cost per QALY and discrete choice experiment-generated public preferences. Appl Health Econ Health Policy
2005;4:249–55. 10.2165/00148365-200504040-00007 [
PubMed: 16466276] [
CrossRef]
- 127.
Kind
P, Hardman
G, Macran
S. UK Population Norms for EQ-5D. York: Centre for Health Economics, University of York; 1999.
- 128.
Georghiou
T, Bardsley
M. Exploring the Cost of Care at the End of Life. London: Nuffield Trust; 2014.
- 129.
Salem
R, Lewandowski
RJ, Mulcahy
MF, Riaz
A, Ryu
RK, Ibrahim
S, et al.
Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology
2010;138:52–64. 10.1053/j.gastro.2009.09.006 [
PubMed: 19766639] [
CrossRef]
- 130.
- 131.
Duvoux
C, Roudot-Thoraval
F, Decaens
T, Pessione
F, Badran
H, Piardi
T, et al.
Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology
2012;143:986–94. 10.1053/j.gastro.2012.05.052 [
PubMed: 22750200] [
CrossRef]
- 132.
NHS Blood and Transplant Organ Donation and Transplantation Directorate – Liver Advisory Group. Update on the HCC Down-staging Service Evaluation. Bristol: NHS Blood and Transplant; 2019.
- 133.
Samuel
D, Coilly
A. Management of patients with liver diseases on the waiting list for transplantation: a major impact to the success of liver transplantation. BMC Med
2018;16:113. 10.1186/s12916-018-1110-y [
PMC free article: PMC6069832] [
PubMed: 30064414] [
CrossRef]
- 134.
NHS Blood and Transplant. UK Transplant Registry Data. Bristol: NHS Blood and Transplant; 2019.
- 135.
de’Angelis
N, Landi
F, Carra
MC, Azoulay
D. Managements of recurrent hepatocellular carcinoma after liver transplantation: a systematic review. World J Gastroenterol
2015;21:11185–98. 10.3748/wjg.v21.i39.11185 [
PMC free article: PMC4607916] [
PubMed: 26494973] [
CrossRef]
- 136.
National Institute for Health and Care Excellence (NICE). Midostaurin for Untreated Acute Myeloid Leukaemia [TA523]. London: NICE; 2018. URL:
www.nice.org.uk/Guidance/TA523 (accessed 3 September 2019).
- 137.
National Institute for Health and Care Excellence (NICE). Tisagenlecleucel for Treating Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years [TA554]. London: NICE; 2018. URL:
www.nice.org.uk/guidance/ta554 (accessed 3 September 2019).
- 138.
National Institute for Health and Care Excellence (NICE). Gemtuzumab Ozogamicin for Untreated Acute Myeloid Leukaemia [TA545]. London: NICE; 2018. URL:
www.nice.org.uk/guidance/ta545 (accessed 3 September 2019).
- 139.
Mazzaferro
V, Sposito
C, Bhoori
S, Romito
R, Chiesa
C, Morosi
C, et al.
Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology
2013;57:1826–37. 10.1002/hep.26014 [
PubMed: 22911442] [
CrossRef]
- 140.
National Institute for Health and Care Excellence (NICE). Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma [TA189]. London: NICE; 2010.
- 141.
- 142.
National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal 2013. London: NICE; 2013. [
PubMed: 27905712]
- 143.
White
JD, Dale
M, Morgan
H, Sewell
B, Carolan-Rees
G. Comissioning Through Evaluation: Selective Internal Radiation Therapy (SIRT). Cardiff: CEDAR Healthcare Technology Research Centre; 2017.
- 144.
Woodcock
F, Doble
B, CANCER 2015 Consortium. Mapping the EORTC-QLQ-C30 to the EQ-5D-3L: an assessment of existing and newly developed algorithms. Med Decis Making
2018;38:954–67. 10.1177/0272989X18797588 [
PubMed: 30226101] [
CrossRef]
- 145.
- 146.
Szende
A, Janssen
B, Cabasés
J, editors. Self-reported Population Health: An International Perspective Based on EQ-5D. Dordrecht: Springer; 2014. 10.1007/978-94-007-7596-1 [
PubMed: 29787044] [
CrossRef]
- 147.
Russell
RT, Feurer
ID, Wisawatapnimit
P, Lillie
ES, Castaldo
ET, Pinson
CW. Profile of health-related quality of life outcomes after liver transplantation: univariate effects and multivariate models. HPB
2008;10:30–7. 10.1080/13651820701883106 [
PMC free article: PMC2504851] [
PubMed: 18695756] [
CrossRef]
- 148.
Estraviz
B, Quintana
JM, Valdivieso
A, Bilbao
A, Padierna
A, de Urbina
JO, Sarabia
S. Factors influencing change in health-related quality of life after liver transplantation. Clin Transplant
2007;21:481–99. 10.1111/j.1399-0012.2007.00672.x [
PubMed: 17645707] [
CrossRef]
- 149.
Telles-Correia
D, Barbosa
A, Mega
I, Mateus
E, Monteiro
E. When does quality of life improve after liver transplantation? A longitudinal prospective study. Transplant Proc
2009;41:904–5. 10.1016/j.transproceed.2009.01.051 [
PubMed: 19376385] [
CrossRef]
- 150.
Tome
S, Wells
JT, Said
A, Lucey
MR. Quality of life after liver transplantation. A systematic review. J Hepatol
2008;48:567–77. 10.1016/j.jhep.2007.12.013 [
PubMed: 18279999] [
CrossRef]
- 151.
Younossi
ZM, McCormick
M, Price
LL, Boparai
N, Farquhar
L, Henderson
JM, Guyatt
G. Impact of liver transplantation on health-related quality of life. Liver Transpl
2000;6:779–83. 10.1053/jlts.2000.18499 [
PubMed: 11084068] [
CrossRef]
- 152.
Bryan
S, Ratcliffe
J, Neuberger
JM, Burroughs
AK, Gunson
BK, Buxton
MJ. Health-related quality of life following liver transplantation. Qual Life Res
1998;7:115–20. 10.1023/a:1008849224815 [
PubMed: 9523492] [
CrossRef]
- 153.
Vilgrain
V, Abdel-Rehim
M, Sibert
A, Ronot
M, Lebtahi
R, Castéra
L, Chatellier
G, SARAH Trial Group. Radioembolisation with yttrium-90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. Trials
2014;15:474. 10.1186/1745-6215-15-474 [
PMC free article: PMC4265525] [
PubMed: 25472660] [
CrossRef]
- 154.
National Institute for Health and Care Excellence (NICE). Lenvatinib and Sorafenib for Treating Differentiated Thyroid Cancer after Radioactive Iodine. (TA535). London: NICE; 2018.
- 155.
Vogel
A, Cervantes
A, Chau
I, Daniele
B, Llovet
J, Meyer
T, et al.
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol
2018;29:iv238–55. 10.1093/annonc/mdy308 [
PubMed: 30285213] [
CrossRef]
- 156.
Arber
M, Garcia
S, Veale
T, Edwards
M, Shaw
A, Glanville
JM. Performance of Ovid MEDLINE search filters to identify health state utility studies. Int J Technol Assess Health Care
2017;33:472–80. 10.1017/S0266462317000897 [
PubMed: 29065942] [
CrossRef]
- 157.
- 158.
Liver Advisory Group – NHS Blood and Transplant. Update on the HCC Down-staging Service Evaluation. Bristol: NHS Blood and Transplant; 2018.
- 159.
She
WH, Cheung
TT, Yau
TC, Chan
AC, Chok
KS, Chu
FS, et al.
Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection. Hepatobiliary Surg Nutr
2014;3:185–93. 10.3978/j.issn.2304-3881.2014.07.09 [
PMC free article: PMC4141294] [
PubMed: 25202695] [
CrossRef]
- 160.
Kooby
DA, Egnatashvili
V, Srinivasan
S, Chamsuddin
A, Delman
KA, Kauh
J, et al.
Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol
2010;21:224–30. 10.1016/j.jvir.2009.10.013 [
PubMed: 20022765] [
CrossRef]
- 161.
Kwok
PC, Leung
KC, Cheung
MT, Lam
TW, Szeto
LT, Chou
SQ, et al.
Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres. J Gastroenterol Hepatol
2014;29:1897–904. 10.1111/jgh.12621 [
PubMed: 24734957] [
CrossRef]
- 162.
Song
JE, Jung
KS, Kim
DY, Song
K, Won
JY, Lee
HW, et al.
Transarterial radioembolization versus concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma: a propensity score matching analysis. Int J Radiat Oncol Biol Phys
2017;99:396–406. 10.1016/j.ijrobp.2017.05.049 [
PubMed: 28871990] [
CrossRef]
- 163.
Oladeru
OT, Miccio
JA, Yang
J, Xue
Y, Ryu
S, Stessin
AM. Conformal external beam radiation or selective internal radiation therapy-a comparison of treatment outcomes for hepatocellular carcinoma. J Gastrointest Oncol
2016;7:433–40. 10.21037/jgo.2015.10.04 [
PMC free article: PMC4880776] [
PubMed: 27284477] [
CrossRef]
- 164.
Rühl
R, Seidensticker
M, Peters
N, Mohnike
K, Bornschein
J, Schütte
K, et al.
Hepatocellular carcinoma and liver cirrhosis: assessment of the liver function after yttrium-90 radioembolization with resin microspheres or after CT-guided high-dose-rate brachytherapy. Dig Dis
2009;27:189–99. 10.1159/000218352 [
PubMed: 19546558] [
CrossRef]
- 165.
D’Avola
D, Lñarrairaegui
M, Bilbao
JI, Martinez-Cuesta
A, Alegre
F, Herrero
JI, et al.
A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma. Hepatogastroenterology
2009;56:1683–8. [
PubMed: 20214218]
- 166.
Carr
BI, Kondragunta
V, Buch
SC, Branch
RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer
2010;116:1305–14. 10.1002/cncr.24884 [
PMC free article: PMC2829376] [
PubMed: 20066715] [
CrossRef]
- 167.
Kallini
JR, Gabr
A, Ali
R, Abouchaleh
N, Riaz
A, Baker
T, et al.
Pretransplant intra-arterial liver-directed therapy does not increase the risk of hepatic arterial complications in liver transplantation: a single-center 10-year experience. Cardiovasc Intervent Radiol
2018;41:231–8. 10.1007/s00270-017-1793-z [
PubMed: 28900709] [
CrossRef]
- 168.
Gabr
A, Abouchaleh
N, Ali
R, Vouche
M, Atassi
R, Memon
K, et al.
Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization. Eur J Radiol
2017;93:100–6. 10.1016/j.ejrad.2017.05.022 [
PubMed: 28668402] [
CrossRef]
- 169.
Riaz
A, Ryu
RK, Kulik
LM, Mulcahy
MF, Lewandowski
RJ, Minocha
J, et al.
Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol
2009;27:5734–42. 10.1200/JCO.2009.23.1282 [
PubMed: 19805671] [
CrossRef]
- 170.
Biederman
DM, Titano
JJ, Korff
RA, Fischman
AM, Patel
RS, Nowakowski
FS, et al.
Radiation segmentectomy versus selective chemoembolization in the treatment of early-stage hepatocellular carcinoma. J Vasc Interv Radiol
2018;29:30–7.e2. 10.1016/j.jvir.2017.08.026 [
PubMed: 29169782] [
CrossRef]
- 171.
Ahmad
J, Rhee
J, Carr
BI. The effects of hepatic artery chemotherapy on viral hepatitis in patients with hepatocellular carcinoma. Dig Dis Sci
2005;50:331–5. 10.1007/s10620-005-1606-0 [
PubMed: 15745096] [
CrossRef]
- 172.
Padia
SA, Johnson
GE, Horton
KJ, Ingraham
CR, Kogut
MJ, Kwan
S, et al.
Segmental yttrium-90 radioembolization versus segmental chemoembolization for localized hepatocellular carcinoma: results of a single-center, retrospective, propensity score-matched study. J Vasc Interv Radiol
2017;28:777–85.e1. 10.1016/j.jvir.2017.02.018 [
PubMed: 28365172] [
CrossRef]
- 173.
Padia
SA, Johnson
GE, Horton
KJ, Kwan
S, Vaidya
S, Ingraham
CR, et al.
Segmental yttrium-90 radioembolization versus chemoembolization for localized hepatocellular carcinoma. J Clin Oncol
2016;34:4084. 10.1200/JCO.2016.34.15_suppl.4084 [
PubMed: 28365172] [
CrossRef]
- 174.
Newell
PH, Wu
Y, Hoen
H, Uppal
R, Thiesing
JT, Sasadeusz
K, et al.
Multimodal treatment of unresectable hepatocellular carcinoma to achieve complete response results in improved survival. HPB
2015;17:454–60. 10.1111/hpb.12377 [
PMC free article: PMC4402057] [
PubMed: 25580988] [
CrossRef]
- 175.
Taussig
MD, Irene Koran
ME, Mouli
SK, Ahmad
A, Geevarghese
S, Baker
JC, et al.
Neutrophil to lymphocyte ratio predicts disease progression following intra-arterial therapy of hepatocellular carcinoma. HPB
2017;19:458–64. 10.1016/j.hpb.2017.01.013 [
PubMed: 28190710] [
CrossRef]
- 176.
McDevitt
JL, Alian
A, Kapoor
B, Bennett
S, Gill
A, Levitin
A, et al.
Single-center comparison of overall survival and toxicities in patients with infiltrative hepatocellular carcinoma treated with yttrium-90 radioembolization or drug-eluting embolic transarterial chemoembolization. J Vasc Interv Radiol
2017;28:1371–7. 10.1016/j.jvir.2017.05.017 [
PubMed: 28689934] [
CrossRef]
- 177.
Akinwande
O, Kim
D, Edwards
J, Brown
R, Philips
P, Scoggins
C, et al.
Is radioembolization (90Y) better than doxorubicin drug eluting beads (DEBDOX) for hepatocellular carcinoma with portal vein thrombosis? A retrospective analysis. Surg
Oncol
2015;24:270–5. 10.1016/j.suronc.2015.06.008 [
PubMed: 26133576] [
CrossRef]
- 178.
Philips
P, Edwards
J, Russell
B, Scoggins
CR, Martin
RC. A comparative analysis of transarterial therapy for unresectable hepatocellular carcinoma with portal vein thrombosis: radioembolization 90Y versus doxorubicin drug eluting beads (DEB-DOX). Ann Surg Oncol
2015;22:S109.
- 179.
Biederman
DM, Titano
JJ, Bishay
VL, Durrani
RJ, Dayan
E, Tabori
N, et al.
Radiation segmentectomy versus TACE combined with microwave ablation for unresectable solitary hepatocellular carcinoma up to 3 cm: a propensity score matching study. Radiology
2017;283:895–905. 10.1148/radiol.2016160718 [
PubMed: 27930089] [
CrossRef]
- 180.
Biederman
D, Titano
J, Bishay
V, Durrani
R, Dayan
E, Schwartz
M, et al.
Radiation segmentectomy vs. microwave ablation for unresectable solitary hepatocellular carcinoma < 3 cm: a propensity score matching study. J Vasc Interv Radiol
2016;27:S5–6. 10.1016/j.jvir.2015.12.030 [
CrossRef]
- 181.
Padia
SA, Chewning
RH, Kogut
MJ, Ingraham
CR, Johnson
GE, Bhattacharya
R, et al.
Outcomes of locoregional tumor therapy for patients with hepatocellular carcinoma and transjugular intrahepatic portosystemic shunts. Cardiovasc Intervent Radiol
2015;38:913–21. 10.1007/s00270-014-1009-8 [
PubMed: 25373795] [
CrossRef]
- 182.
Radunz
S, Saner
FH, Treckmann
J, Rekowski
J, Theysohn
JM, Müller
S, et al.
Hepatic artery and biliary complications in liver transplant recipients with radioembolization bridging treatment for hepatocellular carcinoma. Clin Transplant
2017;31. 10.1111/ctr.13096 [
PubMed: 28836737] [
CrossRef]
- 183.
Ali
R, Gabr
A, Abouchaleh
N, Al Asadi
A, Mora
RA, Kulik
L, et al.
Survival analysis of advanced HCC treated with radioembolization: comparing impact of clinical performance status versus vascular invasion/metastases. Cardiovasc Intervent Radiol
2018;41:260–9. 10.1007/s00270-017-1791-1 [
PubMed: 28879621] [
CrossRef]
- 184.
Kudo
M. Systemic therapy for hepatocellular carcinoma: 2017 update. Oncology
2017;93(Suppl. 1):135–46. 10.1159/000481244 [
PubMed: 29258077] [
CrossRef]
- 185.
National Institute for Health and Care Excellence (NICE). Pertuzumab with Trastuzumab and Docetaxel for Treating HER2-positive Breast Cancer. [TA509]. London: NICE; 2018.
- 186.
NHS England. Schedule 2 – The Services. Liver Transplantation Service (Adults). Service Specification 170003/S. Redditch: NHS England; 2017.
- 187.
NHS Blood and Transplant. Organ Donation and Transplantation. Cambridge: NHS Blood and Transplant; 2018.
- 188.
National Institute for Health and Care Excellence (NICE). SIR-Spheres for Treating Inoperable Hepatocellular Carcinoma. Medtech Innovation Briefing [MIB63]. London: NICE; 2016. URL:
www.nice.org.uk/advice/mib63 (accessed 8 May 2019).
- 189.
Department of Health and Social Care (DHSC). NHS Reference Costs 2016–17. London: DHSC; 2017.
